Every 424B that VolitionRx Limited (VNRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VNRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VNRX filings page.
VolitionRx Limited is registering $1.55-priced equity: up to 2,960,000 shares of common stock with accompanying warrants to purchase up to 1,480,000 shares. The units are sold at a combined public offering price of $1.55 per share and accompanying warrant; each Warrant has an exercise price of $1.55 and a five-year term. The offering includes Pre-Funded Warrants for purchasers who would otherwise exceed 4.99% (or elect 9.99%) ownership, with an exercise price of $0.001 per Pre-Funded Warrant. Net proceeds are estimated at approximately $4.1 million assuming full exercise of Pre-Funded Warrants and no exercise of the Warrants; proceeds are intended for research, development, clinical studies, commercialization, working capital and partial repayment of specified convertible notes.
VolitionRx Limited (VNRX) is proposing a registered offering of common stock, detachable warrants and pre-funded warrants pursuant to a preliminary prospectus supplement to a shelf registration statement. The offering includes pre-funded warrants for purchasers who would exceed 4.99% (or elect 9.99%) ownership limits. The company disclosed a one-for-20 reverse stock split effective April 28, 2026, reported 8,627,191 shares outstanding as of May 26, 2026, and stated a public float of approximately $29.7 million under Form S-3 instruction I.B.6. Net proceeds are intended for research and development, clinical studies, commercialization, working capital and repayment of certain Lind Notes.
VolitionRx Limited is offering 11,550,000 shares of common stock together with accompanying warrants to purchase 11,550,000 shares at a combined price of $0.52 per share-and-warrant, including $0.01 allocated to each warrant. The warrants are exercisable immediately at $0.60 per share and expire five years from issuance, subject to a 4.99% or 9.99% beneficial ownership limitation. The underwriter has a 30‑day option to purchase up to an additional 1,732,500 shares and accompanying warrants.
The offering implies a gross proceed of $6,006,000, underwriting discounts of $420,420, and proceeds to the company before expenses of $5,585,580; net proceeds are estimated at approximately $5.4 million. The company plans to use the funds for research and product development, clinical studies, commercialization, working capital and general corporate purposes, including potential strategic acquisitions. Shares outstanding are expected to be 115,532,020 immediately after the offering, excluding any warrant exercises. Certain directors and officers agreed to purchase an aggregate of 254,229 units. The warrants will not be listed, which may limit their liquidity. Underwriter warrants equal to 7.0% of shares sold (808,500, or 929,775 if the option is fully exercised) carry a $0.63 exercise price.
VolitionRx Limited is launching an underwritten public offering of common stock bundled with five-year common stock warrants, with each share sold together with one warrant. The warrants are immediately exercisable, include 4.99% or 9.99% beneficial ownership caps, and will not be listed on any exchange, limiting their liquidity.
The company plans to use net proceeds for research and product development, clinical studies, commercialization, working capital and potential strategic acquisitions. VolitionRx highlights substantial existing warrants, options and RSUs and warns that new investors will face immediate and potentially further dilution. Auditors have issued a “going concern” opinion, and the company does not expect to pay cash dividends, so returns would rely on share price appreciation.